AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06040099
- Locations
- πΊπΈ
Research Site, Milwaukee, Wisconsin, United States
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1240
- Registration Number
- NCT06040086
- Locations
- π»π³
Research Site, Hochiminh, Vietnam
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 720
- Registration Number
- NCT06034743
- Locations
- π»π³
Research Site, Hochiminh city, Vietnam
PRostate Olaparib Real World Evidence Study
Recruiting
- Conditions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06031805
- Locations
- π«π·
Research Site, Vantoux, France
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 372
- Registration Number
- NCT06023589
- Locations
- π¬π§
Research Site, Nottingham, United Kingdom
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 320
- Registration Number
- NCT06020014
- Locations
- π»π³
Research Site, Hue, Vietnam
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 460
- Registration Number
- NCT06015737
- Locations
- π¬π§
Research Site, London, United Kingdom
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT06008093
- Locations
- πΊπΈ
Research Site, Milwaukee, Wisconsin, United States
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06005493
- Locations
- π¬π§
Research Site, Wirral, United Kingdom
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
Active, not recruiting
- Conditions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 192
- Registration Number
- NCT05999877
- Locations
- πͺπΈ
Research Site, Murcia, Region De Murcia, Spain
Β© Copyright 2024. All Rights Reserved by MedPath